Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025
Iterum Therapeutics (Nasdaq: ITRM) will release its third quarter 2025 financial results before U.S. market open on Friday, November 14, 2025.
Management will host a conference call at 8:30 a.m. ET the same day to discuss results and provide a business update. Dial-in numbers are 833-470-1428 (domestic) and 404-975-4839 (international) with Access Code 459214. Investors can pre-register at https://events.q4inc.com/attendee/334189282. An audio webcast will be available after the call under Financials & Filings in the Investors section at www.iterumtx.com.
Iterum Therapeutics (Nasdaq: ITRM) pubblicherà i risultati finanziari del terzo trimestre 2025 prima dell'apertura del mercato statunitense venerdì 14 novembre 2025.
La direzione terrà una conference call alle 8:30 ET dello stesso giorno per discutere i risultati e fornire un aggiornamento sull'attività. I numeri per la chiamata sono 833-470-1428 (nazionale) e 404-975-4839 (internazionale) con il codice di accesso 459214. Gli investitori possono preregistrarsi su https://events.q4inc.com/attendee/334189282. Una webcast audio sarà disponibile dopo la chiamata nella sezione Investitori sotto Finanziari e Depositi sul sito www.iterumtx.com.
Iterum Therapeutics (Nasdaq: ITRM) publicará sus resultados financieros del tercer trimestre de 2025 antes de la apertura del mercado estadounidense el viernes 14 de noviembre de 2025.
La dirección llevará a cabo una llamada de conferencia a las 8:30 a.m. ET ese mismo día para discutir los resultados y proporcionar una actualización del negocio. Los teléfonos para llamar son 833-470-1428 (doméstico) y 404-975-4839 (internacional) con el código de acceso 459214. Los inversores pueden pre-registrarse en https://events.q4inc.com/attendee/334189282. Una retransmisión de audio estará disponible después de la llamada en la sección de Inversores en www.iterumtx.com.
Iterum Therapeutics (Nasdaq: ITRM)은 미국 시장 개장 전인 2025년 11월 14일 금요일에 제3분기 2025년 재무 실적을 발표합니다.
경영진은 같은 날 동부표준시 8:30에 컨퍼런스 콜을 주최하여 결과를 논의하고 비즈니스 업데이트를 제공합니다. 다이얼 인 번호는 국내 833-470-1428, 국제 404-975-4839이며 접속 코드 459214입니다. 투자자는 https://events.q4inc.com/attendee/334189282에서 사전 등록할 수 있습니다. 콜 이후에는 Investors 섹션의 Financials & Filings 아래에서 오디오 웹캐스트를 이용할 수 있습니다 www.iterumtx.com.
Iterum Therapeutics (Nasdaq : ITRM) publiera ses résultats financiers du troisième trimestre 2025 avant l’ouverture du marché américain le vendredi 14 novembre 2025.
La direction animera une conférence téléphonique à 8h30 HE le même jour pour discuter des résultats et fournir une mise à jour de l’activité. Les numéros d’appel sont 833-470-1428 (domestique) et 404-975-4839 (international) avec le code d’accès 459214. Les investisseurs peuvent pré-s’inscrire sur https://events.q4inc.com/attendee/334189282. Une webdiffusion audio sera disponible après l’appel sous Financials & Filings dans la section Investisseurs sur www.iterumtx.com.
Iterum Therapeutics (Nasdaq: ITRM) wird seine finanziellen Ergebnisse des dritten Quartals 2025 vor der Eröffnung des US-Marktes am Freitag, dem 14. November 2025 bekannt geben.
Das Management wird am selben Tag um 8:30 Uhr Osten eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen und ein Geschäft-Update zu geben. Die Einwahlnummern lauten 833-470-1428 (inländisch) und 404-975-4839 (international) mit dem Zugangscode 459214. Investoren können sich vorregistrieren unter https://events.q4inc.com/attendee/334189282. Ein Audio-Webcast wird nach dem Anruf unter Financials & Filings im Bereich Investors unter www.iterumtx.com verfügbar sein.
Iterum Therapeutics (Nasdaq: ITRM) سيصدر النتائج المالية للربع الثالث من 2025 قبل افتتاح السوق الأمريكية في يوم الجمعة 14 نوفمبر 2025.
ستعقد الإدارة مكالمة مؤتمر في 8:30 صباحاً بتوقيت شرق الولايات المتحدة في اليوم نفسه لمناقشة النتائج وتقديم تحديث للأعمال. أرقام الاتصال هي 833-470-1428 (محلي) و 404-975-4839 (دولي) مع رمز الوصول 459214. يمكن للمستثمرين التسجيل المسبق في https://events.q4inc.com/attendee/334189282. سيكون webcast صوتي متاحاً بعد المكالمة في قسم المالية والملفات ضمن قسم المستثمرين على www.iterumtx.com.
- None.
- None.
DUBLIN, Ireland and CHICAGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its third quarter 2025 financial results before the open of the U.S. financial markets on Friday, November 14, 2025. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company’s financial results and provide an update on its business.
To access the call please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to Access Code 459214. To pre-register for this call, please go to the following link: https://events.q4inc.com/attendee/334189282. The audio webcast can be accessed under “Financials & Filings” in the Investors section of the Company’s website at www.iterumtx.com following the call.
About Iterum Therapeutics plc
Iterum Therapeutics plc is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received approval of its NDA for ORLYNVAH™ (oral sulopenem) for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options by the U.S. Food and Drug Administration and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit www.iterumtx.com.
Investor Contact:
Judy Matthews
Chief Financial Officer
312-778-6073
IR@iterumtx.com
FAQ
When will Iterum Therapeutics (ITRM) report Q3 2025 financial results?
What time is Iterum Therapeutics' Q3 2025 earnings call and how can I join?
How can I pre-register for Iterum Therapeutics' November 14, 2025 conference call?
Will Iterum Therapeutics provide a webcast of the Q3 2025 call and where is it posted?
What will Iterum Discuss on the November 14, 2025 call for ITRM shareholders?
